Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam

European Journal of Clinical Pharmacology

Volumn 49, Issue 4, 1996, Pages 305-308

  Bonnabry, P ^a   Leemann, T ^a   Dayer, P ^a  

^a Faculty of Medicine   (Switzerland)

Author keywords

CYP2C9; Cytochrome P 450; Drug metabolism; Lornoxicam; NSAIDs

Indexed keywords

5' HYDROXYLORNOXICAM; CYTOCHROME P450; DICLOFENAC; DRUG METABOLITE; IBUPROFEN; LORNOXICAM; MEFENAMIC ACID; PHENYTOIN; SULFAPHENAZOLE; TOLBUTAMIDE; UNCLASSIFIED DRUG; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

EID: 0030028246     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00226332     Document Type: Article

References (21)

1. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell 12:1-51
2. Hermans JJ, Thijssen HH (1993) Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 110:482-490
3. Veronese ME, Mackenzie PI, Doecke CJ, Mc Manus ME, Miners JO, Birkett DJ (1991) Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 175:1112-1118
4. Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN, Mc Manus ME (1991) Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 31:125-130
5. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450:a role for P-450 2C9 in the etiology of (S)-warfarin drug interactions. Chem Res Toxicol 5:54-59
6. Leemann T, Transon C, Dayer P (1993) Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29-34
7. Leemann T, Bonnabry P, Dayer P (1994) Stereo- and nonstereo-selective oxidation by hepatic P450TB (CYP2C): The major elimination pathway of (±)-ibuprolen in humans. Clin Pharmacol Ther 55:208
8. Bonnabry P, Leemann T, Dayer P (1994) Biotransformation by hepatic P450TB (CYP2C) controls mefenamic acid elimination. Clin Pharmacol Ther 55:139
9. Kondo M, Leemann T, Dayer P (1992) Piroxicam 5′-hydroxylation is catalyzed by human cytochrome P450TB (CYP2C). Experientia 48:A7
10. Zhao J, Leemann T, Dayer P (1992) In vitro oxidation of oxicam NSAIDs by a human liver cytochrome P450. Life Sci 51:575-581
11. Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D (1990) Pharmacokinetics of lornoxicam in man. Postgrad Med J 66 [Suppl 4]:S22-S27
12. Turner P, Johnston A (1990) Clinical pharmacokinetic studies with lornoxicam. Postgrad Med J 66 [Suppl 4]:S28-S29
13. Back DJ, Tjia JF, Karbwang J, Colbert J (1988) In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles. sulphonamides and quinolines. Br J Clin Pharmacol 26:23-29
14. Von Bahr C, Groth CG, Jansson H, Lundgren G, Lind M, Glaumann H (1980) Drug metabolism in human liver in vitro: Establishment of a human liver bank. Clin Pharmacol Ther 27:711-725
15. Dayer P, Kronbach T, Eichelbaum M, Meyer UA (1987) Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Biochem Pharmacol 36:4145-4152
16. Dayer P, Leemann T, Striberni R (1989) Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P450db1 activity. Clin Pharmacol Ther 45:34-40
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
18. Gascon MP, Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41:573-578
19. Holford N. MKMODEL (version 4.42) User Manual (1991) Biosoft, Cambridge, UK
20. Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55:170-171
21. Cornish-Bowden A (1974) A simple graphical method for determining the inhibition constant of mixed, uncompetitive and non-competitive inhibitors. Biochem J 137: 143-144